Эозинофильный нейротоксин (EDN) в кале

Eosinophil cationic protein (ECP), ImmunoCAP quantifies a key eosinophil granule mediator to assess eosinophilic inflammation in allergic disease. The test supports diagnosis, grading of activity, and therapeutic monitoring in asthma, atopic dermatitis, allergic rhinitis, food allergy, and related atopic conditions. Because circulating ECP reflects eosinophil activation, serial measurements can help track exacerbations and response to anti‑inflammatory interventions, including inhaled corticosteroids and dietary elimination when clinically indicated.

Eosinophil cationic protein is a cationic ribonuclease released from eosinophil granules during IgE‑dependent allergen activation. Structurally and functionally related to pancreatic ribonuclease, ECP exerts cytotoxic effects on epithelial, mast, and smooth muscle cells as well as fibroblasts, and it modulates immunity by acting on lymphocytes to promote a Th2‑skewed response. Because eosinophils populate mucosal surfaces of the respiratory and gastrointestinal tracts and many parenchymal organs, ECP release contributes to the diverse clinical spectrum of allergic disease. Serum and plasma concentrations rise during allergic responses and may be used as a marker of disease activity and for treatment monitoring. Circulating ECP generally parallels eosinophil burden and correlates with the intensity of mucosal inflammation. In asthma, ECP levels often track clinical severity and seasonal variability but do not correlate with bronchial hyperreactivity. Marked elevations occur with invasive helminth infections (e.g., Schistosoma mansoni) and during flares of atopic dermatitis; the highest values are seen in hypereosinophilic syndrome of myeloproliferative origin. Increasing ECP can support the initial evaluation of allergic disorders, while declining values accompany resolution of inflammation and eosinophilia. Serial testing can aid therapeutic decisions, including titration of inhaled glucocorticoids in asthma and assessment of response to dietary modification in atopic dermatitis. ECP elevation is not specific for allergy. Increased concentrations have been observed in bacterial sinusitis, renal neoplasms, and respiratory syncytial virus infection. Drug reaction with eosinophilia and systemic symptoms (DRESS) is another notable context; this severe hypersensitivity syndrome—most often associated with phenytoin, phenobarbital, carbamazepine, sulfonamides, minocycline, and doxycycline—is characterized by rash, internal organ involvement, and hematologic abnormalities, and is accompanied by substantially increased ECP.